
|Articles|August 1, 2004
FDA approves Botox for hyperhidrosis tx
Irvine, Calif. - Sweat has a new enemy. Botox (botulinum toxin type A), developed by Allergan, has been approved by the U.S. Food and Drug Administration (FDA) to treat hyperhidrosis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











